Guggenheim started coverage on shares of Metsera (NASDAQ:MTSR – Free Report) in a research report report published on Tuesday morning, MarketBeat reports. The brokerage issued a buy rating and a $56.00 price target on the stock.
Several other brokerages have also recently issued reports on MTSR. Evercore ISI assumed coverage on Metsera in a research note on Tuesday. They set an “outperform” rating on the stock. Bank of America initiated coverage on shares of Metsera in a report on Tuesday. They issued a “buy” rating and a $38.00 price target for the company.
Check Out Our Latest Stock Report on MTSR
Metsera Stock Performance
Metsera Company Profile
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Featured Articles
- Five stocks we like better than Metsera
- How to invest in marijuana stocks in 7 steps
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- Profitably Trade Stocks at 52-Week Highs
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- With Risk Tolerance, One Size Does Not Fit All
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
